C4710
Monoclonal Anti-Cyclin A antibody produced in mouse
clone CY-A1, ascites fluid
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Scegli un formato
Scegli un formato
Cambia visualizzazione
About This Item
Prodotti consigliati
Origine biologica
mouse
Coniugato
unconjugated
Forma dell’anticorpo
ascites fluid
Tipo di anticorpo
primary antibodies
Clone
CY-A1, monoclonal
PM
antigen 60 kDa
contiene
15 mM sodium azide
Reattività contro le specie
mouse, human, monkey, bovine
tecniche
immunocytochemistry: suitable
microarray: suitable
western blot: 1:1,000 using a mouse NIH 3T3 cell extract
Isotipo
IgG2a
N° accesso UniProt
Condizioni di spedizione
dry ice
Temperatura di conservazione
−20°C
modifica post-traduzionali bersaglio
unmodified
Informazioni sul gene
human ... CCNA2(890)
mouse ... Ccna2(12428)
Descrizione generale
Cyclin A is a nuclear protein during S phase and it binds both cdk2 and cdc2. The availability of monoclonal antibody reacting specifically with cyclin A enables the subcellular detection and localization of cyclin A and the measurement of relative differences in cyclin A levels as a function of cell cycle phase.
Specificità
The antibody recognizes an epitope present in amino acids 162-433 of bovine cyclin A. No cross-reactivity is detected with other cyclins (cyclin B, D, or E).
Immunogeno
recombinant bovine cyclin A.
Applicazioni
Monoclonal Anti-Cyclin A antibody produced in mouse is suitable for:
- immunocytochemistry
- microarray
- western blotting at a dilution of 1:1,000 using a mouse NIH 3T3 cell extract
Esclusione di responsabilità
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Non trovi il prodotto giusto?
Prova il nostro Motore di ricerca dei prodotti.
Raccomandato
N° Catalogo
Descrizione
Determinazione del prezzo
Codice della classe di stoccaggio
10 - Combustible liquids
Classe di pericolosità dell'acqua (WGK)
nwg
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
Non trovi la versione di tuo interesse?
Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Matthew Hoare et al.
Nature cell biology, 18(9), 979-992 (2016-08-16)
Senescence, a persistent form of cell-cycle arrest, is often associated with a diverse secretome, which provides complex functionality for senescent cells within the tissue microenvironment. We show that oncogene-induced senescence is accompanied by a dynamic fluctuation of NOTCH1 activity, which
Qing-Hua Zhang et al.
The Journal of cell biology, 216(10), 3133-3143 (2017-08-19)
Cyclin A2 is a crucial mitotic Cdk regulatory partner that coordinates entry into mitosis and is then destroyed in prometaphase within minutes of nuclear envelope breakdown. The role of cyclin A2 in female meiosis and its dynamics during the transition
Emma L Hesketh et al.
Cell cycle (Georgetown, Tex.), 14(3), 333-341 (2015-02-07)
The minichromosome maintenance complex (MCM2-7) is the putative DNA helicase in eukaryotes, and essential for DNA replication. By applying serial extractions to mammalian cells synchronized by release from quiescence, we reveal dynamic changes to the sub-nuclear compartmentalization of MCM2 as
J E Dazard et al.
Oncogene, 19(33), 3693-3705 (2000-08-19)
p53 transcription factor is mutated in most skin cell carcinomas and in more than 50% of all human malignancies. One of its transcriptional targets is MDM2, which in turn down-regulates p53. The role of the p53/MDM2 regulatory loop upon genotoxic
Chunyan Weng et al.
International journal of oncology, 42(1), 327-337 (2012-11-09)
Androgen deprivation therapy of prostate cancer with estrogens shows significant cardiovascular side-effects. To develop effective prostate cancer therapeutic agent(s) with minimal cardiovascular side-effects, we compared the effects of various estrogen receptor (ER) ligands on the modulation of dihydrotestosterone (DHT) actions
Filtri attivi
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.
